REG - Hikma Pharmaceutical - Notice of Results

Hikma PharmaceuticalsAnnouncement

10/02/2025 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250210:nRSJ5044Wa&default-theme=true

RNS Number : 5044W  Hikma Pharmaceuticals Plc  10 February 2025

London, 10 February 2025 - Hikma Pharmaceuticals PLC (Hikma, Group), will
announce its financial results for the year ended 31 December 2024 on
Wednesday 26 February 2025.

A recording of the presentation and slide deck will be available on the
Group's website at www.hikma.com (http://www.hikma.com) from 7:00am GMT. Hikma
will also hold a live Q&A call for analysts at 9:00am GMT, and a recording
will be made available on the website.

 

To join via conference call please dial:

United Kingdom (Local): +44 20 3936 2999

United Kingdom (Toll-Free): +44 800 358 1035

United States (Local): +1 845 213 3398

United States (Toll-Free): +1 855 9796 654

Global Dial-In Numbers
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.netroadshow.com_conferencing_global-2Dnumbers-3FconfId-3D76687%26d%3DDwMFaQ%26c%3DbZnDpUh0cTwskH9nIvyseq2tJ5dkOfcF56epRyP8Xxo%26r%3D-ez93etbg_mYALTIk80-LeSiBK2c108TWoFgseu2Zxlo93lWK05OsNNYOjhJyLj_%26m%3DsQyuFn75BWaqK2jfrfULUqyHcP3qWdcAj7NJ0_ZvtNuwC8RRXnf-esBNCHExEwpD%26s%3DS4sLCl3iv0_gCx_tqK-jPrtHq6zCCAf5S3K81c064AI%26e%3D&data=05%7C02%7CLKalisse%40Hikma.com%7Cd3877b22227b485efbcd08dd3bce973b%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C638732481035373992%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=%2FKABWewOXC1Kks%2FmAnPZc8EEecXwZ414ux%2FTxxIwN9I%3D&reserved=0)

Access Code: 292359

 

 

- ENDS -

 

Enquiries

 

Hikma Pharmaceuticals PLC
 

 Susan Ringdal                                                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations
 Layan Kalisse                                                                +44 (0)20 7399 2788/ +44 (0)7970 709912

 Senior Associate, Investor Relations

 

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGMZRGNGKZG